MX360857B - Régimen de dosificación para inhibidores de janus quinasa (jak). - Google Patents

Régimen de dosificación para inhibidores de janus quinasa (jak).

Info

Publication number
MX360857B
MX360857B MX2015000871A MX2015000871A MX360857B MX 360857 B MX360857 B MX 360857B MX 2015000871 A MX2015000871 A MX 2015000871A MX 2015000871 A MX2015000871 A MX 2015000871A MX 360857 B MX360857 B MX 360857B
Authority
MX
Mexico
Prior art keywords
jak
janus
mammal
dosage regime
quinasa
Prior art date
Application number
MX2015000871A
Other languages
English (en)
Spanish (es)
Other versions
MX2015000871A (es
Inventor
Andrea J Gonzales
Sallie B Cosgrove
Phyllis B Malpas
Michael Rolf Stegemann
Wendy Turner Collard
Original Assignee
Zoetis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48901189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX360857(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Llc filed Critical Zoetis Llc
Publication of MX2015000871A publication Critical patent/MX2015000871A/es
Publication of MX360857B publication Critical patent/MX360857B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MX2015000871A 2012-07-20 2013-07-18 Régimen de dosificación para inhibidores de janus quinasa (jak). MX360857B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261674289P 2012-07-20 2012-07-20
US201361815803P 2013-04-25 2013-04-25
PCT/US2013/051015 WO2014015107A1 (en) 2012-07-20 2013-07-18 Dosing regimen for janus kinase (jak) inhibitors

Publications (2)

Publication Number Publication Date
MX2015000871A MX2015000871A (es) 2015-05-07
MX360857B true MX360857B (es) 2018-11-20

Family

ID=48901189

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015000871A MX360857B (es) 2012-07-20 2013-07-18 Régimen de dosificación para inhibidores de janus quinasa (jak).

Country Status (25)

Country Link
US (1) US9522151B2 (enExample)
EP (1) EP2874630B1 (enExample)
JP (2) JP6022063B2 (enExample)
KR (2) KR20150028299A (enExample)
CN (2) CN104470525A (enExample)
AU (1) AU2013292547B2 (enExample)
BR (1) BR112015000808A2 (enExample)
CA (1) CA2878867C (enExample)
CY (1) CY1121436T1 (enExample)
DK (1) DK2874630T3 (enExample)
ES (1) ES2707627T3 (enExample)
HK (2) HK1209314A1 (enExample)
HR (1) HRP20182088T1 (enExample)
HU (1) HUE042771T2 (enExample)
IN (1) IN2015DN00370A (enExample)
LT (1) LT2874630T (enExample)
MX (1) MX360857B (enExample)
NZ (1) NZ703152A (enExample)
PL (1) PL2874630T3 (enExample)
PT (1) PT2874630T (enExample)
RS (1) RS58242B1 (enExample)
SI (1) SI2874630T1 (enExample)
SM (1) SMT201900044T1 (enExample)
WO (1) WO2014015107A1 (enExample)
ZA (1) ZA201500134B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3290421B1 (en) 2013-02-22 2019-01-02 Pfizer Inc Combination of pyrrolo [2, 3 -d]pyrimidine derivatives with one or more additional agents as inhibitors of janus- related kinases (jak)
JP6585158B2 (ja) 2014-08-12 2019-10-02 ファイザー・インク ヤヌスキナーゼの阻害に有用なピロロ［２，３−ｄ］ピリミジン誘導体
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11780848B2 (en) 2015-10-16 2023-10-10 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
CA3251507A1 (en) 2015-10-16 2025-05-21 Abbvie Inc Use of a solid dosage form comprising (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide for treating rheumatoid arthritis
WO2017143014A1 (en) * 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
CN107098908B (zh) * 2016-02-23 2021-01-08 欣凯医药科技(上海)有限公司 一种吡咯并嘧啶类化合物的制备方法和应用
KR102195348B1 (ko) 2018-11-15 2020-12-24 에이치케이이노엔 주식회사 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물
CN111499641B (zh) * 2019-01-30 2021-06-04 格格巫（珠海）生物科技有限公司 一种jak抑制剂及其制备方法
US11992490B2 (en) 2019-10-16 2024-05-28 Incyte Corporation Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP)
EP4263559A1 (en) 2020-12-18 2023-10-25 Boehringer Ingelheim Animal Health USA Inc. Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof
MX2023010835A (es) * 2021-03-16 2023-09-29 Hk Inno N Corp Nuevas sales de compuestos heterocíclicos como inhibidores de proteínas quinasas y sus usos.
CA3216017A1 (en) * 2021-04-22 2022-10-27 Shengjian Huang Pharmaceutical composition containing jak3/jak1/tbk1 selective inhibitor and medical use thereof
WO2024259429A2 (en) * 2023-06-16 2024-12-19 The University Of Chicago Methods and compositions for pharmaceutically relevant interactions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50087B (sr) * 1998-06-19 2009-01-22 Pfizer Products Inc., Pirolo (2,3-d) pirimidin jedinjenja
PT2384326E (pt) * 2008-08-20 2014-06-09 Zoetis Llc Compostos de pirrolo[2,3-d]pirimidina

Also Published As

Publication number Publication date
JP2017019816A (ja) 2017-01-26
HK1252083A1 (zh) 2019-05-17
HUE042771T2 (hu) 2019-07-29
CN108354938A (zh) 2018-08-03
AU2013292547B2 (en) 2017-05-04
CN104470525A (zh) 2015-03-25
RS58242B1 (sr) 2019-03-29
ZA201500134B (en) 2016-08-31
US9522151B2 (en) 2016-12-20
BR112015000808A2 (pt) 2017-06-27
EP2874630A1 (en) 2015-05-27
DK2874630T3 (en) 2019-01-28
KR20150028299A (ko) 2015-03-13
JP2015522620A (ja) 2015-08-06
IN2015DN00370A (enExample) 2015-06-12
SI2874630T1 (sl) 2019-04-30
CA2878867C (en) 2018-01-09
ES2707627T3 (es) 2019-04-04
AU2013292547A1 (en) 2015-01-22
EP2874630B1 (en) 2018-12-05
CA2878867A1 (en) 2014-01-23
JP6022063B2 (ja) 2016-11-09
SMT201900044T1 (it) 2019-02-28
US20150126535A1 (en) 2015-05-07
PT2874630T (pt) 2019-01-31
HK1209314A1 (en) 2016-04-01
PL2874630T3 (pl) 2019-04-30
MX2015000871A (es) 2015-05-07
LT2874630T (lt) 2019-02-11
KR20170034949A (ko) 2017-03-29
HRP20182088T1 (hr) 2019-02-08
NZ703152A (en) 2016-03-31
CY1121436T1 (el) 2020-05-29
WO2014015107A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
MX360857B (es) Régimen de dosificación para inhibidores de janus quinasa (jak).
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
MX2016000271A (es) Metodos para el tratamiento de la esofagitis eosinofilica mediante la administracion de un inhibidor de il-4r.
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2019009853A (es) Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres.
NI201600051A (es) Combinaciones de inhibidores de histona desacetilasa y farmacos inmunomoduladores
AR101740A1 (es) Terapia de combinación y composiciones
MX2018016287A (es) Derivados de pirazolopirimidina como inhibidor de cinasa.
BR112015020350A2 (pt) derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida e seu uso como inibidores de phd
BR112016029853A2 (pt) compostos de indazol substituído como inibidores de irak4
MX373964B (es) Compuestos aromaticos multisustituidos como inhibidores de serina proteasa.
BR112014004504A2 (pt) "composto como inibidor de c-kit cinase, seu uso, composição farmacêutica, e medicamento para o tratamento de uma doença mediada por uma cinase"
EA201391390A1 (ru) Циклопропиламины в качестве ингибиторов lsd
BR112017003433A2 (pt) inibidores espirocíclicos de catepsina c
MX2018014231A (es) Metodos y composiciones para tratar canceres resistentes al inhibidor de la via de cinasas proteicas activadas por mitogeno (mapk), no cinasas extracelulares de señal regulada (erk).
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
BR112015003729A2 (pt) composto de fórmula estrutural i; composição farmacêutica; método de tratamento de uma doença mediada por caminho do hif; método de tratamento de uma doença causada por proliferação anormal de células; e método para alcançar um efeito em um paciente
MX379286B (es) INHIBIDORES DE PCSK9 PARA USARSE EN EL TRATAMIENTO DE PACIENTES CON HIPERCOLESTEROLEMIA FAMILIAR HETEROCIGOTA (HFHe).
CR20140036A (es) Compuesto inhibidor de la señalización de la trayectoria notch
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
MX2016005446A (es) Intervenciones a base de angiopoyetina para tratar la malaria cerebral.
CO2017011778A2 (es) Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden

Legal Events

Date Code Title Description
FG Grant or registration